Epilepsy and Dysimmune Diseases: A Continuum? (P10-5.017)

Abstract

<h3>Objective:</h3> The aim of this study was to determine the prevalence of autoimmune and/or endocrine disorders in patients with epilepsy and thus evaluate their associations. <h3>Background:</h3> Epilepsy affects approximately 0.5% to 1.0% of the world’s population. This risk is nearly four times higher in patients with autoimmune and/or endocrine diseases. <h3>Design/Methods:</h3> A retrospective study of Tunisian patients diagnosed with epilepsy in the Neurology department of Monastir. We identified the epidemiological, clinical, electrical features and the presence of autoimmune and/or endocrine disorders. <h3>Results:</h3> Sixty-three patients with epilepsy were included, 34 Men (53%). We have identified eight patients followed for metabolic and/or autoimmune diseases. The mean age: 44 years. Epilepsy was generalized in 85% of cases. Hypothyroidism was the most frequent pathology (50%), followed by type 1 diabetes mellitus (2 patients) and dyslipidemia (2 patients), finally inflammatory bowel disease (2 patients). Antiphospholipid syndrome (APS), systemic lupus erythematosus and Gougerot-Sjögren syndrome were reported in two patients. <h3>Conclusions:</h3> Screening for dysimmune and metabolic disorders in patients followed for epilepsy seems necessary in view of the frequent association and in order to guide antiseizure treatment. <b>Disclosure:</b> Ms. Abbes has nothing to disclose. Dr. Ben Dhia has nothing to disclose. Mariem Mhiri has nothing to disclose. Miss Saad has nothing to disclose. Dr. Gouta has nothing to disclose. Mouna Aissi has nothing to disclose. MAHBOUBA FRIH has nothing to disclose.